Genome-wide linkage analysis of 1,233 prostate cancer pedigrees from the International Consortium for prostate cancer Genetics using novel sumLINK and sumLOD analyses by Christensen, G. Bryce et al.
Genome-wide linkage analysis of 1233 prostate cancer
pedigrees from the International Consortium for Prostate Cancer
Genetics using novel sumLINK and sumLOD analyses
G. Bryce Christensen1, Agnes B. Baffoe-Bonnie2,3,4, Asha George2,3, Isaac Powell2,5, Joan
E. Bailey-Wilson2,4, John D. Carpten2,6, Graham G. Giles7,8, John L. Hopper7,9, Gianluca
Severi7,8, Dallas R. English7,9, William D. Foulkes7,10, Lovise Maehle7,11, Pal Moller7,11, Ros
Eeles7,12, Douglas Easton7,13, Michael D. Badzioch7,14, Alice S. Whittemore15,16,17, Ingrid
Oakley-Girvan15,17, Chih-Lin Hsieh15,18, Latchezar Dimitrov19, Jianfeng Xu19, Janet L.
Stanford20,21, Bo Johanneson20,22, Kerry Deutsch20,23, Laura McIntosh20,21, Elaine A.
Ostrander20,22, Kathleen E. Wiley24, Sarah D. Isaacs24, Patrick C. Walsh24, William B.
Isaacs24, Stephen N. Thibodeau25, Shannon K. McDonnell25, Scott Hebbring25, Daniel J.
Schaid25, Ethan M. Lange26,27, Kathleen A. Cooney26,28, Teuvo L.J. Tammela29, Johanna
Schleutker29, Thomas Paiss30,31, Christiane Maier30,32, Henrik Grönberg33,34, Fredrik
Wiklund33,34, Monica Emanuelsson33,35, James M. Farnham1, Lisa A. Cannon-Albright1,
Nicola J. Camp1, and International Consortium for Prostate Cancer Genetics
1University of Utah ICPCG Group and Division of Genetic Epidemiology, University of Utah
School of Medicine, Salt Lake City, UT, USA 2African American Hereditary Prostate Cancer
ICPCG Group 3Fox Chase Cancer Center, Philadelphia, PA, USA 4National Human Genome
Research Institute, NIH, Bethesda, MD, USA 5Karmanos Cancer Institute, Wayne State
University, Detroit, MI, USA 6Translational Genomics Research Institute, Genetic Basis of Human
Disease Research Division, Phoenix, AZ, USA 7ACTANE consortium ICPCG Group 8Cancer
Epidemiology Centre, The Cancer Council Victoria, Melbourne, Australia 9Centre for Molecular,
Environmental, Genetic and Analytic Epidemiology, School of Population Health, The University
of Melbourne, Melbourne, Australia 10Department of Oncology, McGill University, Montreal,
Quebec, Canada 11The Norwegian Radium Hospital, Oslo, Norway 12Institute of Cancer
Research, Royal Marsden NHS Foundation Trust, Surrey, UK 13Cancer Research UK Genetic
Epidemiology Unit, Cambridge, UK 14Division of Medical Genetics, University of Washington
Medical Center, Seattle, WA, USA 15BC/CA/HI ICPCG Group 16Department of Health Research
and Policy, Stanford School of Medicine, CA, USA 17Stanford Comprehensive Cancer Center,
Stanford School of Medicine, CA, USA 18Department of Urology and Department of Biochemistry
and Molecular Biology, University of Southern California, CA, USA 19Data Coordinating Center for
the ICPCG and Center for Human Genomics, Wake Forest University School of Medicine,
Winston-Salem, NC, USA 20FHCRC ICPCG Group 21Fred Hutchinson Cancer Research Center,
Divisions of Public Health Sciences, Seattle, WA, USA 22Cancer Genetics Branch, National
Institutes of Health, Bethesda, MD, USA 23Institute for Systems Biology, Seattle, WA, USA
24Johns Hopkins University ICPCG Group and Department of Urology, Johns Hopkins Medical
Institutions, Baltimore, MD, USA 25Mayo Clinic ICPCG Group and Mayo Clinic, Rochester, MN,
USA 26University of Michigan ICPCG Group 27Department of Genetics, University of North
Carolina, Chapel Hill, NC, USA 28University of Michigan, Ann Arbor, MI, USA 29University of
Tampere ICPCG Group, University of Tampere and Tampere University Hospital, Tampere,
Finland 30University of Ulm ICPCG Group 31Dept of Urology, University of Ulm, Germany
Corresponding author: G. Bryce Christensen, Division of Genetic Epidemiology, University of Utah School of Medicine, 391, Chipeta
Way, Suite D, Salt Lake City, UT 84108, Phone (801) 581-5070, Fax (801) 581-6052, bryce.christensen@utah.edu.
NIH Public Access
Author Manuscript
Prostate. Author manuscript; available in PMC 2012 August 27.
Published in final edited form as:













32Institute of Human Genetics, University of Ulm, Germany 33University of Umeå ICPCG Group
34Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm,
Sweden 35Oncologic Centre, Umeå University, Umeå, Sweden
Abstract
Background—Prostate cancer is generally believed to have a strong inherited component, but
the search for susceptibility genes has been hindered by the effects of genetic heterogeneity. The
recently developed sumLINK and sumLOD statistics are powerful tools for linkage analysis in the
presence of heterogeneity.
Methods—We performed a secondary analysis of 1233 prostate cancer pedigrees from the
International Consortium for Prostate Cancer Genetics (ICPCG) using two novel statistics, the
sumLINK and sumLOD. For both statistics, dominant and recessive genetic models were
considered. False discovery rate (FDR) analysis was conducted to assess the effects of multiple
testing.
Results—Our analysis identified significant linkage evidence at chromosome 22q12, confirming
previous findings by the initial conventional analyses of the same ICPCG data. Twelve other
regions were identified with genomewide suggestive evidence for linkage. Seven regions (1q23,
5q11, 5q35, 6p21, 8q12, 11q13, 20p11-q11) are near loci previously identified in the initial
ICPCG pooled data analysis or the subset of aggressive prostate cancer (PC) pedigrees. Three
other regions (1p12, 8p23, 19q13) confirm loci reported by others, and two (2p24, 6q27) are novel
susceptibility loci. FDR testing indicates that over 70% of these results are likely true positive
findings. Statistical recombinant mapping narrowed regions to an average of 9 cM.
Conclusions—Our results represent genomic regions with the greatest consistency of positive
linkage evidence across a very large collection of high-risk prostate cancer pedigrees using new
statistical tests that deal powerfully with heterogeneity. These regions are excellent candidates for
further study to identify prostate cancer predisposition genes.
Introduction
Prostate cancer (PC) is believed to have a complex environmental and genetic etiology
potentially involving numerous genes (1). The identification of PCa genes has proven to be
very difficult; genetic heterogeneity is a major issue that hinders progress (2). Confirmations
of reported PC susceptibility loci are infrequent and some of the loci that have been
confirmed by multiple researchers are in chromosomal regions with very few promising
candidate genes (3,4). Luo and Yu reported in 2003 that evidence for PC susceptibility
variants had been reported on all but two human chromosomes (5). These two remaining
chromosomes, 21 (6,7) and 22 (8,9), have subsequently both been implicated. The
International Consortium for Prostate Cancer Genetics (ICPCG) was formed by a large and
diverse group of researchers who have pooled their resources with the intent of deciphering
the principal genetic factors underlying this pervasive disease (10). The ICPCG published
the findings of a conventional linkage analysis using the well-known heterogeneity LOD
(HLOD) statistic and multiple subset analyses based on 1233 high-risk prostate cancer
pedigrees. The study identified several susceptibility loci for further study (8).
Here we present the results of a secondary analysis of the ICPCG pooled pedigree resource
using new genome-wide linkage-based statistics, the sumLINK and sumLOD, to identify PC
susceptibility loci. These new statistics have been shown in simulation studies to be
powerful and robust tools for identifying susceptibility loci in the presence of genetic
heterogeneity (11). The sumLINK/sumLOD approach is well-suited to analysis of pooled
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data resources such as this, because it requires only summary data from each constituent
group which is logistically easier to attain (there are often data privacy and confidentiality
concerns associated with sharing individual raw genotype data and pedigree structures).
Secondary analyses of existing data that are more powerful at addressing genetic
heterogeneity have the potential to refine the original analyses, and identify additional
evidence for PC predispostion genes.
Methods
The sumLINK approach focuses on ‘linked’ pedigrees, which we define to be a pedigree-
specific LOD≥0.588 (p≤0.05). The aim is to identify regions with extreme consistency of
linkage evidence across pedigrees. The sumLINK statistic is the sum of multipoint LOD
scores for all pedigrees that meet the threshold of LOD≥0.588 at a given point in the
genome. This value is computed at intervals of one centimorgan throughout the genome. We
assess the significance of the sumLINK empirically using a unique genome randomization
and shuffling method that simulates the expected consistency of linked pedigrees under null
conditions.(11) Briefly, for each pedigree, the vectors of LOD scores for each chromosome
are connected in random order, with the first and last values connected to form a ‘loop’, and
the loop is broken at a random position to create a randomized, shuffled ‘genomewide’
vector of LOD scores. These vectors are then aligned across pedigrees and values of the
sumLINK statistic are calculated. This procedure is designed to maintain each pedigree’s
potential for linkage signals across the genome, but randomizes consistency of linkage
evidence across pedigrees. Observed peaks are compared with peaks occurring in 1000
iterations of the randomized data in order to establish the expected frequency of peaks with a
similar or greater magnitude for the data in question. This expected frequency may be called
a false positive rate, or FPR.
The sumLOD statistic is a complimentary companion to the sumLINK statistic. The
sumLOD statistic is similar to the sumLINK statistic, but with a reduced inclusion threshold;
all positive pedigree LOD scores at each point in the genome are summed to calculate the
sumLOD statistic. Significance of the sumLOD is determined empirically by the same
genome randomization procedure that is used for the sumLINK. In accordance with the
standards for significant linkage evidence set by Lander and Kruglyak (12), peak sumLINK
and sumLOD values are considered to represent significant evidence of linkage if the
expected frequency of peaks of similar magnitude under null conditions is less than 0.05 per
genome. Peak values are considered to be suggestive evidence of linkage if the expected
frequency is less than one per genome.
We applied the sumLINK and sumLOD procedures to the 1233 PC pedigrees in the ICPCG
pooled pedigree resource. Pedigree characteristics and genotyping details have been
described previously (8). The two statistics were computed at 1-cM increments (N=3502)
throughout the 22 autosomes based on LOD scores from the dominant and recessive
inheritance models that were used in the original ICPCG analysis. The sex chromosomes
were not included in the analysis. 572 pedigrees achieved a maximum LOD score of at least
0.588 at some point in the genome under the dominant inheritance model, and 533 pedigrees
achieved a LOD score of at least 0.588 under the recessive model. Only these pedigrees
contributed to the sumLINK analyses. 1230 pedigrees contributed to the sumLOD analyses
under each model. Empirical significance was computed based on 1000 iterations of the
genome randomization technique.
False positive rates were calculated based on the empirical distributions for each of the four
analyses (dominant and recessive, sumLINK and sumLOD). False discovery rate (FDR) q-
values were estimated to account for the effects of multiple testing that are inherent in the
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usage of multiple models and statistics. Application of FDR methods to multipoint LOD
scores have been shown to be valid provided no fine-mapping markers are used (13). This
requirement is met in the present analysis. The empirical FDR q-value represents the
probability that a given result is a false positive based on the pooled distributions of all four
analyses.
Localization
Loci identified with the sumLINK approach have natural potential for subsequent gene
localization using statistical recombinant mapping (14), as, by definition, there exist a
statistical excess of linked pedigrees contributing to each peak. Hence, for all significant and
suggestive sumLINK peaks we will pursue localization using statistical recombinant
mapping. The genetic marker sets for which pedigrees were genotyped varied between
institutions. Even though the resolution of each separate linkage study map was an average
spacing of 10 cM, the disparity of different marker maps helps fine-mapping efforts. If
pedigrees from different resources are linked to the same region, they can identify regions
smaller than the resolutions of each independent marker map. These genomic segments are
the most probable locations for finding a PC susceptibility gene.
Given the linkage evidence for each pedigree is based on a 10 cM map, most pedigrees will
have a genotyped marker within 5 cM of any given cM position on the genetic map. Hence,
when selecting pedigrees to consider ‘linked’ to a significant or suggestive region, we
identified all pedigrees that achieved LOD≥0.588 within 5 cM of the observed sumLINK
peak. We then examined the LOD score curves for each of these pedigrees and determined
the probable location of recombination events that mark the outer limits of the segregating
chromosomal segment within each pedigree. Recombinant events are estimated to be at the
outer point of an abrupt drop in LOD score, as these positions are statistical evidence for a
loss of genetic sharing by affected pedigree members. A shared chromosomal region
bounded by two recombinant events on each side is an approximate 95% confidence interval
for the consensus region (14).
Results
Figure I shows the genome-wide sumLINK and sumLOD statistics for each model, together
with lines representing the thresholds for significant and suggestive linkage as determined
by the randomization procedure. Results are summarized in Table 1. We identified one locus
with significant linkage evidence, and twelve loci with suggestive linkage evidence. There
were no significant or suggestive linkage peaks identified by the recessive sumLINK
analysis.
Significant linkage evidence was observed at chromosome 22q12 by both the dominant
sumLINK (FPR=0.010, 46 contributing pedigrees) and the dominant sumLOD (FPR=0.032,
454 contributing pedigrees). In addition to both of these findings being genome-wide
significant in their respective single genomewide screens (FPRs < 0.05), after correction for
all four genomewide analyses, the FDR was 0.186. This indicates that under the null
hypothesis, the expected number of peaks at least as extreme as these two is only 0.4
(=0.186×2), and therefore that 1.6 of these 2 peaks are not likely to be from the null
distribution. Since both peaks are at 22q12, this indicates that even after correction for the
four genomewide analyses performed here, there is excellent evidence that the 22q12 locus
is a true positive.
Suggestive peaks are those that in a single genomewide screen would only be expected once
per genome under the null hypothesis. Twelve loci were identified within their respective
single genomewide analyses to have suggestive evidence for linkage. In decreasing order of
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significance, these regions were at chromosomes 5q11 (dominant sumLOD and sumLINK),
2p24 (dominant sumLINK), 6p21 (dominant sumLOD and sumLINK), 19q13 (dominant
sumLINK), 8q12 (dominant and recessive sumLOD), 8p23 (dominant sumLOD), 11q13
(dominant sumLOD), 20p11-q11 (dominant and recessive sumLOD), 6q27 (recessive
sumLOD), 1q23 (dominant sumLINK), 5q35 (dominant sumLINK), and 1p12 (dominant
sumLOD). Loci at 5q11 and 2p24, are perhaps worthy of particular note because although
strictly only suggestive, both were borderline significant (FPRs of 0.059 and 0.089,
respectively). Accounting for the four genomewide analyses, the FDR value associated with
these 18 suggestive and significant peaks (distributed across 13 regions) was 0.262,
indicating that only 4.7 (18×0.262) peaks would have been expected under the null. That is,
we observed 13.3 more peaks than expected and thus 13.3 are likely not from the null.
Hence, there is good evidence that many, although not all, of these loci with suggestive
evidence for linkage are also true positive findings.
Table 2 shows the results of our localization analysis for the seven significant and
suggestive regions identified with the sumLINK analyses. Estimated regions are based on
the observation of two recombination events at each end, indicating an approximate 95%
support interval. The microsatellite markers flanking the two-recombinant region are also
reported. These two-recombinant localization intervals range from 5 to 17 cM, with a mean
of 9.1 cM. Since we included information from all pedigrees with a LOD≥0.588 within 5
cM of the peak, there were some instances where pedigrees showed conflicting evidence
about the location of the shared chromosomal region. In these instances, we selected the
region where the greatest number of pedigrees agreed, and reported the number of
conflicting pedigrees in the table together with the number of supporting pedigrees.
Discussion
We have performed a secondary analysis of data from the largest collection of high-risk
prostate cancer pedigrees ever assembled with new multipoint linkage-based statistics,
sumLINK and sumLOD, which are specifically designed to address genetic heterogeneity.
Three of the thirteen loci that we identified in the present analysis (5q11, 5q35 and 22q12)
correspond directly to peaks that were reported in the original ICPCG analysis using the
conventional HLOD statistic (8). In that analysis, a dominant LOD score of 1.95 was
observed at 22q12, which increased to 3.57 in the subset of pedigrees with at least five
affected family members. Additionally, a non-parametric LOD of 2.28 was reported at 5q12,
and a dominant LOD of 2.05 was reported at 5q35 in the subset of families with mean age at
diagnosis ≤65 years. Two other loci (1q23 and 8q12) are near peaks that were reported in the
first analysis (8). The loci on chromosomes 6p21, 11q13 and 20p11-q11 correspond to
susceptibility loci previously identified in the ICPCG data resource in linkage scans for
aggressive prostate cancer (11,15). The remaining loci have not previously been identified in
pooled ICPCG data, though many of them correspond to findings reported elsewhere in
linkage studies by individual institutions.
The dominant and recessive sumLOD peaks on chromosome 20 appear to be supportive of
the HPC20 locus (16), although it should be noted that the original HPC20 linkage peak was
at 20q13, about 20–30 cM downstream from the peaks we report here. Our tentative
replication of HPC20 is in contrast to an earlier ICPCG study using the same data and a
conventional HLOD approach that failed to replicate this locus (10), although a later ICPCG
study concentrating on aggressive prostate cancer pedigrees did find linkage evidence (15).
The ICPCG aggressive PC linkage study found a dominant LOD score of 2.49 midway
between the dominant and recessive sumLOD peaks that we report here. The observed LOD
score increased to 2.65 in the subset of pedigrees with mean age at onset >65 years. The
present study includes data from most of the pedigrees that were included in the ICPCG
Christensen et al. Page 5













aggressiveness analysis, but the difference in phenotype definition prevents a direct
comparison of the pedigrees that contribute to the results. HPC20 was originally identified
by the Mayo Clinic site (16,17); however, of the 45 pedigrees that exhibited LOD≥0.588
within 5 cM of the dominant sumLOD peak, only 6 were from Mayo Clinic. As seen from
these comparisons, one distinct advantage of the sumLINK and sumLOD statistics is that the
approach inherently identifies subgroups of pedigrees that are genetically alike, and hence
one analysis can encompass what in conventional analyses may take many subset analyses
and multiple testing corrections. It is therefore perhaps not surprising that our results more
closely align with linkage findings for subset-based analyses such as aggressive prostate
cancer (15).
In addition to the findings discussed above, three of the other suggestive linkage regions
reported here support previously identified loci. Our peak at 1p12 falls within a region of
interest reported by other ICPCG member-sites (17). The peak at chromosome 1q23
approximates the HPC1 susceptibility region (19), although the RNASEL candidate gene
proposed as the HPC1 gene (20) is located about 20 Mb beyond the boundary of our support
interval. An ICPCG member-site previously reported linkage at 8p23 (21), a finding that
was recently replicated and refined by combined somatic deletion and fine linkage mapping
(22). The suggestive sumLOD peak at 8p23 is about 4 Mb from the MSR1 PC candidate
gene. Our 19q13 region also corresponds to previously reported linkage for aggressive PC
(23,24).
Our suggestive regions on chromosomes 2p24 and 6q27 appear to be new. Of particular
interest of these new loci is perhaps 2p24. Statistical evidence for 2p24 was borderline
significant, and recently a germline copy number variant at the 2p24 locus has been
associated with aggressive prostate cancer (25). Other notable association studies have
focused on regions identified in this report. Copy number variations at 8p23 and 11q13 have
been implicated in aggressive PC and PC recurrence, respectively (26). Kallikrein genes
KLK2 and KLK3 at chromosome 19q13 have been identified as PC candidate genes (27).
We did not identify linkage evidence to regions that have recently received much attention
due to highly significant and replicable association evidence with PC in genome-wide
association studies. The most compelling of these results are located on chromosomes 8q24,
17q12, and 10q11 (3). It is perhaps not surprising that we did not find any evidence to
support these regions because these SNPs have common minor allele frequencies and very
small effect sizes. The sumLINK and sumLOD are linkage-based statistics, and linkage is
most powerful for finding rarer, more highly-penetrant variants.
The localization procedure we used here to delimit support intervals generated much more
concise intervals than the 1-LOD drop regions reported previously by ICPCG for the four
sumLINK peaks that overlapped with previous findings (8). The intervals reported
previously ranged from 12 to 30 cM with a mean length of 21.2 cM, substantially longer
than the mean length of 9.5 cM we report here for the same 4 regions. A particularly
interesting example of the narrower intervals can be seen in the putative susceptibility locus
at chromosome 5q11–12. The previous analysis of this data identified a suggestive HLOD
peak at 77 cM, with a reported 1-LOD support interval extending from 66—96 cM. In the
present analysis, the sumLINK statistic identified a suggestive linkage peak at 72 cM and a
2-recombinant support interval of only 7 cM which includes the original HLOD peak. This
ability to more narrowly define regions using statistical recombinant mapping was also
illustrated by an earlier candidate region localization study for the chromosome 22q12
susceptibility locus (9). That report had the advantage of LOD score data from several large
pedigrees with fine-mapping markers which were not included in the present results.
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Nonetheless, and as expected, the 2-recombinant localization region we report here supports
the region previously reported in that paper.
Conclusion
A secondary reanalysis of 1233 PC pedigrees using novel linkage statistics identified 13
regions with at least genomewide suggestive evidence for linkage. Eight regions provide
confirmation of loci previously identified by conventional linkage analyses in the same
ICPCG data (8) or the subset of aggressive PC pedigrees (15), three are regions that confirm
loci not seen in the original analyses, but are reported in other linkage studies (18,22–24),
and two are novel loci. One distinct benefit of the sumLINK and sumLOD approach is that
the statistics are based on the identification of pedigrees that are genetically alike at a locus,
and the constituent set of pedigrees may change from locus-to-locus. This both addresses
genetic heterogeneity directly and largely circumvents the need for subset and stratification
analyses that are costly in terms of multiple testing. This is illustrated by the fact that several
of the regions identified here replicate results that were originally found in stratification
analyses. The second advantage for the sumLINK statistic is the natural progression to
statistical recombinant mapping, which appears to hold much promise for narrowing linkage
regions. Furthermore, the FDR approach for correction of multiple genomewide analyses
can better guide interpretation and aid prioritization of findings. Evidence here suggests that
these statistics have the potential to further refine the results of original analyses, and
provide new directions in the pursuit for PC susceptibility genes.
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Genome-wide sumLINK and sumLOD values for dominant and recessive inheritance
models. The line marked “A” in each figure represents the threshold for significant linkage
evidence determined by the genome shuffling process. The line marked “B” shows the
threshold for suggestive linkage evidence.
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